摘要
目的研究在重组人干扰素α2b治疗失败与新诊断慢性髓性白血病患者中采取伊马替尼治疗的临床效果。方法该次研究样本选自该院2014年12月—2016年12月期间收治的20例慢性髓性白血病患者,分组方根据患者的类型,均分为参照组(n=10)与实验组(n=10),参照组为重组人干扰素α2b治疗失败的患者,实验组为新诊断的患者,两组患者均实施伊马替尼治疗,分析对比两组慢性髓性白血病患者总有效率以及不良反应。结果实验组慢性髓性白血病患者不良反应发生率20.00%、总有效率90.00%、完全反应率60.00%、次要反应率0.00%等指标均显著优于参照组不良反应发生率70.00%、总有效率40.00%、完全反应率10.00%、次要反应率40.00%,两组间差异有统计学意义(P<0.05)。结论将伊马替尼治疗应用于重组人干扰素α2b治疗失败与新诊断慢性髓性白血病患者中均可获得一定效果,但是对于新诊断患者治疗效果更显著,可有效控制病情,值得应用。
Objective This paper tries to study the clinical effect of imatinib in the treatment of recombinant human interferon α2 b and the newly diagnosed chronic myeloid leukemia. Methods 20 patients with chronic myeloid leukemia were enrolled in this hospital from December 2014 to December 2016. The patients were divided into the control group（n=10） and the experimental group（n=10） according to the types of patients. The patients in the control group were treated with recombinant human interferon α2 b. The experimental group was newly diagnosed. All patients were treated with imatinib and the total effective rates as well as side effects of the two groups were compared between the two groups. Results The incidence of toxic and side effects in chronic myeloid leukemia pa-tients was 20.00%, the total effective rate was 90.00%, the complete reaction rate was 60.00% and the secondary reaction rate was0.00%. The incidence of toxic and side effects was 70.00%, effective rate of 40.00%, complete response rate of 10.00%, the sec-ondary response rate of 40.00%, there was significant difference between the two groups（P〈0.05）. Conclusion Imatinib therapy is effective in the treatment of recombinant human interferon α2 b and the newly diagnosed chronic myeloid leukemia, and it is more effec-tive for the newly diagnosed patients, which can effectively control the patients ’ conditions and is worth of application.
出处
《世界复合医学》
2017年第4期57-59,共3页
World Journal of Complex Medicine
